基于影像的生物标志物用于预测和评估癌症免疫治疗反应
本文综述了影像学方法在预测和评估癌症免疫治疗反应中的应用进展。目前程序性细胞死亡配体-1(PD-L1)及微卫星高度不稳定和/或错配修复缺陷已用作免疫治疗反应的生物标志物;影像学正被开发用于联合肿瘤免疫微环境特征化,包括基于影像组学的人工智能方法预测和评估免疫治疗反应及免疫相关不良事件风险,以及分子影像技术观察肿瘤对PD-L1等免疫治疗靶点的表达。
要点
- PD-L1及微卫星高度不稳定/错配修复缺陷是目前免疫治疗反应的生物标志物。
- 影像组学人工智能方法可用于预测和评估免疫治疗反应及免疫相关不良事件风险。
- 分子影像技术正在开发用于观察肿瘤对PD-L1等免疫治疗靶点的表达。
诊断标准与关键数值
- 程序性细胞死亡配体-1(PD-L1)及微卫星高度不稳定和/或错配修复缺陷目前用作免疫治疗反应的生物标志物。
- 基于影像组学的人工智能方法被用于特征化肿瘤微环境以预测和评估免疫治疗反应,并预测免疫相关不良事件风险。
- 分子影像技术正在开发用于观察肿瘤对PD-L1等免疫治疗靶点的表达,并确认靶点在原位肿瘤上表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Proper patient selection for immunotherapy is critical, as certain tumor microenvironments are more permissible to therapy than others. Currently, the use of programmed cell death ligand-1 (PD-L1) and microsatellite instability high and/or mismatch repair deficiency are used as biomarkers for immunotherapy response. To improve tumor characterization, methodologies are being developed to combine imaging with tumor immune environment characterization. Imaging of tumors from immunotherapy responders and nonresponders with various imaging modalities has led to the development of criteria that could predict patient response to immunotherapy. Additionally, radiomics-based artificial intelligence methods are being used to characterize tumor microenvironments to predict and evaluate immunotherapy responses, as well as to predict risk of immune-related adverse events. Molecular imaging techniques are also being developed for various modalities to observe tumor expression of immunotherapy targets, such as PD-L1 and, to confirm the target is being expressed on resident tumors. In all, the advancements of imaging techniques to define tumor immunologic characteristics will help to stratify patients who are more likely to respond to immunotherapies. Keywords: Computer Aided Diagnosis (CAD), Computer Applications-Virtual Imaging, Efficacy Studies, MR-Imaging, Molecular Imaging-Cancer, Molecular Imaging-Immunotherapy, Molecular Imaging-Nanoparticles, Molecular Imaging-Probe Development, Molecular Imaging-Target Development, SPECT/CT © RSNA, 2019.
引用
- Wu M, Zhang Y, Zhang Y, et al. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiol Imaging Cancer. 2019. PMID: 33778682. doi:10.1148/rycan.2019190031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。